{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen D"],"funding":["NCI NIH HHS","NCI NIH"],"pagination":["883-894"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10173258"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(7)"],"pubmed_abstract":["Immune checkpoint inhibitors, such as anti-PD-1/PD-L1, have emerged as promising therapies for advanced non-small cell lung cancer (NSCLC). However, approximately 80% of patients do not respond to immunotherapy given alone because of intrinsic or acquired resistance. Radiotherapy (XRT) can overcome PD-1 resistance and improve treatment outcomes, but its efficacy remains suboptimal. The tyrosine phosphatase SHP-2, expressed in some cancers and in immune cells, has been shown to negatively affect antitumor immunity. Our hypothesis was that SHP-2 inhibition in combination with anti-PD-L1 would enhance immune-mediated responses to XRT and synergistically boost antitumor effects in an anti-PD-1-resistant mouse model. We treated 129Sv/Ev mice with anti-PD-1-resistant 344SQ NSCLC adenocarcinoma w"],"journal":["Cancer immunology research"],"pubmed_title":["SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer."],"pmcid":["PMC10173258"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Yang L","Hu Y","Wasley M","Menon H","Verma V","Klein K","Chen D","Ozgen T","Welsh JW","Mosaffa S","Barsoumian HB","Younes AI","Masropour F","Cortez MA"],"additional_accession":[]},"is_claimable":false,"name":"SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.","description":"Immune checkpoint inhibitors, such as anti-PD-1/PD-L1, have emerged as promising therapies for advanced non-small cell lung cancer (NSCLC). However, approximately 80% of patients do not respond to immunotherapy given alone because of intrinsic or acquired resistance. Radiotherapy (XRT) can overcome PD-1 resistance and improve treatment outcomes, but its efficacy remains suboptimal. The tyrosine phosphatase SHP-2, expressed in some cancers and in immune cells, has been shown to negatively affect antitumor immunity. Our hypothesis was that SHP-2 inhibition in combination with anti-PD-L1 would enhance immune-mediated responses to XRT and synergistically boost antitumor effects in an anti-PD-1-resistant mouse model. We treated 129Sv/Ev mice with anti-PD-1-resistant 344SQ NSCLC adenocarcinoma w","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-22T05:12:14.627Z","creation":"2025-04-05T21:13:40.276Z"},"accession":"S-EPMC10173258","cross_references":{"pubmed":["32299915"],"doi":["10.1158/2326-6066.CIR-19-0744","10.1158/2326-6066.cir-19-0744"]}}